Authors: Ellis, MJ Coop, A Singh, B Mauriac, L Llombert-Cussac, A Janicke, F Miller, WR Evans, DB Dugan, M Brady, C Quebe-Fehling, E Borgs, M

Citation: Mj. Ellis et al., Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial, J CL ONCOL, 19(18), 2001, pp. 3808-3816